ADCs are having yet another resurgence, driven now by the phenomenal success of ENHERTU, as well as significant innovation in antibody engineering, linker technology, and a diversifying range of conjugates from cytokines to PROTACs. The clinical benefit that can be achieved, even in what many had thought a crowded space with a very high bar around pursuing HER2 proves once again that Oncology is not limited to only incremental advances, but true game-changers can be delivered on even in what have been thought to be well-trodden therapeutic modalities. The example of ENHERTU underscores the need for careful deliberation around clinical path, the development of TPPs, and further raises the bar now for the next HER2-targeting program, whether bispecific or cell therapy or next gen modality. And this idea applies broadly as companies look to bring their novel ADC products into well-validated and highly competitive spaces. With this panel of experts, we will have an engaging dialogue around these opportunities and challenges.
- Jeffrey M. Bockman, PhD, EVP, Head of Oncology, Commercial BioConsulting, Lumanity
- Giles Gallant, MD, BPharm PhD FOPQ, Senior VP, Global Head, Oncology Development,Daiichi-Sankyo
- Seema Kantak, PhD., Senior Vice President, Biotherapeutics, Exelixis
- Hans-Georg Lerchen, PhD, CSO, Vincerx
- Timothy Lowinger, PhD, CSO, Mersana Therapeutics
- Bilal Piperdi, VP of Clinical Development, Gilead Sciences, Inc.